Search

Your search keyword '"Ines, Ushiro-Lumb"' showing total 3 results
Start Over Author "Ines, Ushiro-Lumb" Journal american journal of transplantation
3 results on '"Ines, Ushiro-Lumb"'

1. Liver graft outcomes from donors with vaccine induced thrombosis and thrombocytopenia (VITT): United Kingdom multicenter experience

Author

Andreas Prachalias, Khalid Sharif, Rebecca Sanabria-Mateos, Katherine Quist, Darius F. Mirza, Owen L. Cain, Will Lester, John Forsythe, Hermien Hartog, Angus Hann, Phillip L R Nicolson, Ines Ushiro-Lumb, Anisa Nutu, George H.B. Greenhall, Douglas Thorburn, John Isaac, Ye Htun Oo, Abhishek Chauhan, M. Thamara P. R. Perera, Desley Neil, and Joerg M. Pollok

Subjects
medicine.medical_specialty, Tissue and Organ Procurement, Lymphocyte, medicine.medical_treatment, Liver transplantation, medicine.disease_cause, Gastroenterology, Autoimmunity, Internal medicine, medicine, Humans, Immunology and Allergy, Pharmacology (medical), Platelet, Vein, Vaccines, Transplantation, biology, business.industry, Graft Survival, Thrombosis, medicine.disease, Thrombocytopenia, Tissue Donors, medicine.anatomical_structure, Liver, biology.protein, Antibody, business, Platelet factor 4
Abstract

Vaccine-induced immune thrombosis and thrombocytopenia (VITT) syndrome is a new entity, characterised by severe thrombocytopenia and multiple sites of thrombosis1 . The presumed mechanism is driven by anti-platelet factor 4 (PF4) antibodies causing platelet activation1 . Donors with VITT syndrome have a particular relevance for liver transplantation (LT), due to the associated risk of passenger lymphocyte syndrome, and a predisposition for porto-mesenteric or hepatic vein thrombosis2 .

Published
2022
Full Text
View/download PDF

2. Organ transplantation from deceased donors with vaccine-induced thrombosis and thrombocytopenia

Author

Lisa Mumford, Quentin A. Hill, Muhammad Arslan Khurram, Rommel Ravanan, Sanjay Mehra, George H. B. Greenhall, Gavin J. Pettigrew, Ismail H. Mohamed, Reza Motallebzadeh, Nicholas Torpey, Chris J. Callaghan, Hemant Sharma, Gabriel C Oniscu, David J. Roberts, M. Thamara P. R. Perera, Gareth Jones, Ian Currie, Beverley Hunt, Jorge Mascaro, Darius F. Mirza, Marius Berman, Sue Pavord, Douglas Thorburn, Nicos Kessaris, Olive McGowan, Jay Nath, Sue Madden, Debabrata Roy, Karthik Santhanakrishnan, Sern Lim, Hermien Hartog, Aileen Marshall, Marc Clancy, Christopher J.E. Watson, Francis Calder, John Forsythe, Joerg-Matthias Pollok, and Ines Ushiro-Lumb

Subjects
kidney transplantation/nephrology, Organ transplantation, Immunology and Allergy, Pharmacology (medical), Letter to the Editor, media_common, Brain dead, Vaccines, biology, Vaccination, Brain, Heparin, Thrombosis, Tissue Donors, infection and infectious agents – viral: influenza, Antibody, medicine.drug, 2019-20 coronavirus outbreak, medicine.medical_specialty, Tissue and Organ Procurement, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), media_common.quotation_subject, clinical research/practice, Letter to the Editors, Insult, medicine, Humans, donors and donation: donor follow‐up, Platelet activation, Letters to the Editor, Transplantation, SARS-CoV-2, business.industry, Autoantibody, COVID-19, Organ Transplantation, medicine.disease, Thrombocytopenia, coagulation and hemostasis, Immunology, biology.protein, Etiology, business, liver transplantation/hepatology, autoantibody, Platelet factor 4
Abstract

Vaccine-induced thrombosis and thrombocytopenia (VITT) may follow immunisation with the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2. Autoantibodies to platelet factor 4 (PF4) may mediate VITT through antibody-dependent platelet activation, though the underlying etiology is uncertain. Anti-PF4 antibodies are also seen in heparin-induced thrombocytopenia, though most cases of VITT do not have prior heparin exposure. More than 20 million people in the United Kingdom (UK) have received the ChAdOx1 nCoV-19 vaccine.

Published
2021
Full Text
View/download PDF

3. Screening for SARS‐CoV‐2 in potential deceased organ donors

Author

Jasvir Parmar, Ian Currie, John Forsythe, Dale Gardiner, Jonathon Olsburgh, Chris J. Callaghan, Ines Ushiro-Lumb, and Marius Berman

Subjects
donors and donation: donor‐derived infections, 2019-20 coronavirus outbreak, medicine.medical_specialty, Tissue and Organ Procurement, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), infectious disease, organ procurement and allocation, Case Report, 030230 surgery, clinical research/practice, 03 medical and health sciences, 0302 clinical medicine, editorial/personal viewpoint, lung transplantation/pulmonology, Internal medicine, Immunology and Allergy, Medicine, Humans, Pharmacology (medical), Infectious disease (athletes), donors and donation: deceased, Letter to the Editor, Transplantation, Lung donor, business.industry, Transmission (medicine), SARS-CoV-2, infection and infectious agents – viral, COVID-19, respiratory system, Tissue Donors, respiratory tract diseases, business
Abstract

We describe a case of proven transmission of SARS‐CoV‐2 from lung donor to recipient. The donor had no clinical history or findings suggestive of infection with SARS‐CoV‐2 and tested negative by reverse transcriptase polymerase chain reaction (RT‐PCR) on a nasopharyngeal (NP) swab obtained within 48 h of procurement. Lower respiratory tract testing was not performed. The recipient developed fever, hypotension, and pulmonary infiltrates on posttransplant day (PTD) 3, and RT‐PCR testing for SARS‐CoV‐2 on an NP swab specimen was non‐reactive, but positive on bronchoalveolar lavage (BAL) fluid. One thoracic surgeon present during the transplantation procedure developed COVID‐19. Sequence analysis of isolates from donor BAL fluid (obtained at procurement), the recipient, and the infected thoracic surgeon proved donor origin of recipient and health‐care worker (HCW) infection. No other organs were procured from this donor. Transplant centers and organ procurement organizations should perform SARS‐CoV‐2 testing of lower respiratory tract specimens from potential lung donors, and consider enhanced personal protective equipment for HCWs involved in lung procurement and transplantation.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results